DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for multiple symmetric lipomatosis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMultiple symmetric lipomatosis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for multiple symmetric lipomatosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
mitofusin 2 (MFN2) — MFN2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6JFK · 1.997 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
The 2009 paper on symmetric lipomatoses in female patients describes six women: three with benign (multiple) symmetric lipomatosis and three with female zonal obesity. In the benign symmetric lipomatosis cases, fat deposition was massive, firm, and symmetric around the neck and shoulder girdle, and was clearly associated with alcohol abuse or liver disease. No malignant tumours of the upper airways were found. In the female zonal obesity cases, fat accumulated mainly at the buttocks and thighs but spared the feet and hands; tenderness was common, and there was familial predisposition. Histology in both groups showed normal fatty tissue that was neither encapsulated nor septally divided. The authors propose that the term symmetric lipomatoses covers two separate disorders.
A 1989 case report describes a 61-year-old man with multiple symmetric lipomatosis who had the striking appearance characteristic of the condition and a history of alcohol abuse. He had undergone surgical treatment three times at other hospitals before admission. A 2009 case report describes a Japanese man with benign symmetric lipomatosis associated with atopic dermatitis and chronic alcohol abuse. The paper notes that histologically, cells in the abnormal lipomatous areas are indistinguishable from normal fat.
No drug treatment is mentioned in any of these abstracts. The only intervention described is surgery, and in the 1989 case it was repeated without preventing recurrence. There is no evidence from these reports of any pharmacological therapy, no response rates, no survival data, and no controlled trials. What is still missing is any clinical trial of a drug for this condition, any systematic attempt to stratify patients by aetiology (alcohol-related versus familial versus other), and funding for such research.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Dermatology · 2009 · 29 citations
Symmetric Lipomatoses in Female Patients
AbstractBACKGROUND: Symmetric lipomatoses are characterized by marked symmetric deposition of diffusely distributed fatty tissue. Though relatively common disorders, they are rather rarely reported in the literature, possibly being misdiagnosed as general obesity. While the differential diagnosis of symmetric lipomatosis versus general obesity may not appear difficult in males, it is obviously problematic in females. OBSERVATIONS: We describe the findings in 6 representative female patients with symmetric lipomatoses: 3 with benign (multiple) symmetric lipomatosis and 3 with female zonal obesity. The former disorder was characterized by massive, firm, symmetric fat deposition predominantly around the neck and shoulder girdle and was clearly associated with alcohol abuse and/or liver disease. There were no malignant tumors of the upper airways. In the latter case, fatty tissue had accumulated mainly at the buttocks and thighs but characteristically spared the feet and hands. Tenderness was a common symptom. This disorder showed familial predisposition. Histology in both cases revealed normal fatty tissue which was neither encapsulated nor septally divided. CONCLUSIONS: We suggest that the term 'symmetric lipomatoses' refers to two separate disorders, benign (multiple) symmetric lipomatosis and female zonal obesity.
A Case of Multiple Symmetric Lipomatosis (Madelungʼs Disease)
AbstractA case of multiple symmetric lipomatosis in a 61-year-old man is described. The patient had the striking appearance that characterizes multiple symmetric lipomatosis. He had a history of alcohol abuse. Before admission to our institution, he underwent surgical treatment three times at other hospitals. We describe his clinical course and review the literature.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
